EpiVax and FDA Scientists Identify Immunogenicity Risks in Generic Teriparatide Impurities
Key Insights
EpiVax (search) and FDA scientists published a study evaluating immunogenicity risks of peptide-related impurities in generic teriparatide products using computational and experimental methods.
Multiple impurities showed higher predicted immunogenic potential than reference teriparatide, with experimental analyses confirming enhanced HLA (search) binding and T-cell responses.
The research identified a potentially tolerogenic region within teriparatide that could be disrupted by sequence changes in impurities, affecting drug safety.
EpiVax (search), Inc., in collaboration with U.S. Food and Drug Administration (FDA) and CUBRC (search), Inc. scientists, has published new research revealing significant immunogenicity risks associated with peptide-related impurities in generic teriparatide products. The study, titled "Immunogenicity Risk Assessment of Peptide-Related Impurities Identified in Generic Teriparatide Products," provides critical insights for ensuring the safety and comparability of generic peptide drugs.
Regulatory Context and Clinical Significance
Teriparatide, a recombinant peptide used to treat osteoporosis, is among the peptide products highlighted in recent FDA guidance recommending that applicants assess immunogenicity risk for synthetic generics submitted under abbreviated new drug applications (ANDA). While establishing active pharmaceutical ingredient sameness remains a key regulatory requirement, impurities arising from manufacturing processes may introduce sequence changes with the potential to generate new T-cell epitopes.
Comprehensive Assessment Methodology
The research team systematically evaluated teriparatide and several theoretical or observed impurities using EpiVax (search)'s PANDA approach, which employs three orthogonal methods: in silico assessment leveraging T-cell epitope prediction and characterization tools (EpiMatrix® and JanusMatrix®), in vitro HLA (search) binding assays, and human T-cell assays.
Key Findings on Immunogenic Potential
The investigators identified multiple impurities with higher predicted immunogenic potential than the reference teriparatide sequence using computational tools. Experimental analyses corroborated these predictions, revealing enhanced HLA (search) binding and T-cell responses for several impurities compared to teriparatide itself.
Notably, the study revealed a potentially tolerogenic region within the teriparatide sequence that may reduce responses to the drug, but that could be disrupted by sequence changes in the impurities. This finding has important implications for understanding how manufacturing-related impurities could affect the overall immunological profile of generic peptide products.
Industry Impact and Applications
"This collaboration with FDA scientists underscores the power of combining robust computational and wet-lab methods to better understand and mitigate immunogenicity risks in generic peptide development," said Dr. Vibha Jawa, Chief Scientific Officer at EpiVax (search). "Our findings offer a practical framework for developers navigating the FDA guidance on impurity assessment and highlight opportunities to strengthen peptide drug safety."
The study may help generic peptide manufacturers identify impurities of concern that would contribute to immunogenicity and thus should be controlled in the generic drug product. This research provides a systematic approach for evaluating the immunological consequences of peptide impurities, which is increasingly important as more generic peptide products enter development.
Research Support and Collaboration
The research was performed by EpiVax (search) in collaboration with CUBRC (search), Inc. and FDA contributors, supported by FDA contract HHSF223018186C. This collaborative effort demonstrates the importance of public-private partnerships in advancing regulatory science and improving drug safety assessment methodologies for complex biological products.